Inovio Pharmaceuticals Inc (NASDAQ:INO)

8.50
Delayed Data
As of Jun 18
 -0.32 / -3.63%
Today’s Change
5.81
Today|||52-Week Range
33.79
-3.95%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Medical Specialties
MARKET CAP
$1.8B

Company Description

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline include VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Contact Information

Inovio Pharmaceuticals, Inc.
660 West Germantown Pike
Plymouth Meeting Pennsylvania 19462-1111
P:(267) 440-4200
Investor Relations:
(484) 362-0076

Employees

Shareholders

Mutual fund holders20.55%
Individual stakeholders2.02%
Other institutional16.01%

Top Executives

J. Joseph KimPresident, Chief Executive Officer & Director
Jacqueline E. SheaChief Operating Officer & Executive Vice President
Peter D. KiesChief Financial Officer
Stephen KemmerrerSenior Vice President-Engineering Development
Kate E. BroderickSenior Vice President-Research & Development